CY1119030T1 - Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων - Google Patents

Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων

Info

Publication number
CY1119030T1
CY1119030T1 CY20171100604T CY171100604T CY1119030T1 CY 1119030 T1 CY1119030 T1 CY 1119030T1 CY 20171100604 T CY20171100604 T CY 20171100604T CY 171100604 T CY171100604 T CY 171100604T CY 1119030 T1 CY1119030 T1 CY 1119030T1
Authority
CY
Cyprus
Prior art keywords
bone cancer
cancer pain
signs
big
big signs
Prior art date
Application number
CY20171100604T
Other languages
English (en)
Inventor
Daniel Zamanillo-Castanedo
Hernández José Miguel Vela
Carlos Plata-Salaman
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.
Publication of CY1119030T1 publication Critical patent/CY1119030T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η εφεύρεση αφορά στη χρήση ενός δεσμού σίγμα, ιδιαίτερα ενός δεσμού σίγμα του τύπου (I) για να αποτραπεί ή/και να θεραπευτεί ο πόνος που συνδέεται με τον καρκίνο των οστών.
CY20171100604T 2010-12-03 2017-06-08 Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων CY1119030T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382330A EP2460519A1 (en) 2010-12-03 2010-12-03 Use of sigma ligands in bone cancer pain
PCT/EP2011/071584 WO2012072782A1 (en) 2010-12-03 2011-12-02 Use of sigma ligands in bone cancer pain
EP11794082.5A EP2646025B1 (en) 2010-12-03 2011-12-02 Use of sigma ligands in bone cancer pain

Publications (1)

Publication Number Publication Date
CY1119030T1 true CY1119030T1 (el) 2018-01-10

Family

ID=43629676

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100604T CY1119030T1 (el) 2010-12-03 2017-06-08 Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων

Country Status (33)

Country Link
US (1) US20130324535A1 (el)
EP (2) EP2460519A1 (el)
JP (1) JP6027014B2 (el)
KR (1) KR101855358B1 (el)
CN (1) CN103313709B (el)
AR (1) AR084730A1 (el)
BR (1) BR112013013369A8 (el)
CA (1) CA2819442C (el)
CO (1) CO6781549A2 (el)
CY (1) CY1119030T1 (el)
DK (1) DK2646025T3 (el)
ES (1) ES2626672T3 (el)
HR (1) HRP20170818T1 (el)
HU (1) HUE033488T2 (el)
IL (1) IL226706A (el)
LT (1) LT2646025T (el)
MA (1) MA34878B1 (el)
ME (1) ME02852B (el)
MX (1) MX343773B (el)
MY (1) MY171994A (el)
NZ (1) NZ612119A (el)
PL (1) PL2646025T3 (el)
PT (1) PT2646025T (el)
RS (1) RS56081B1 (el)
RU (1) RU2585095C2 (el)
SG (1) SG190745A1 (el)
SI (1) SI2646025T1 (el)
TN (1) TN2013000227A1 (el)
TR (1) TR201708567T4 (el)
TW (1) TWI629060B (el)
UA (1) UA112638C2 (el)
WO (1) WO2012072782A1 (el)
ZA (1) ZA201304966B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
CA2922330A1 (en) * 2013-09-12 2015-03-19 Laboratorios Del Dr. Esteve, S.A. Nsaid and sigma receptor ligand combinations
JP2016540771A (ja) 2013-12-17 2016-12-28 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ セロトニン−ノルアドレナリン再取り込み阻害薬(snri)およびシグマ受容体リガンドの組み合わせ
EP3082790A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
AR109024A1 (es) * 2016-07-12 2018-10-17 Esteve Labor Dr Uso de ligandos del receptor sigma en el dolor post-herpético
CN112165955A (zh) * 2018-05-21 2021-01-01 益普生生物制药有限公司 抑制骨癌引起的异常性疼痛
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
KR20210151572A (ko) 2020-06-05 2021-12-14 주식회사 허밍아비스 발열체 조성물 및 이를 이용한 마스크 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517872T1 (de) * 2003-06-26 2011-08-15 Novartis Ag Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis
JP5139061B2 (ja) * 2004-08-27 2013-02-06 ラボラトリオス デル ドクトール エステベ エセ.ア. シグマ受容体阻害剤
SI1781618T1 (sl) * 2004-08-27 2013-01-31 Laboratorios Del Dr. Esteve, S.A. Inhibitorji sigma receptorja
US8202872B2 (en) * 2006-03-01 2012-06-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Also Published As

Publication number Publication date
HRP20170818T1 (hr) 2017-08-25
EP2460519A1 (en) 2012-06-06
JP2014501732A (ja) 2014-01-23
CN103313709B (zh) 2017-05-24
SI2646025T1 (sl) 2017-07-31
RU2013130222A (ru) 2015-01-10
IL226706A (en) 2015-07-30
MX343773B (es) 2016-11-23
AR084730A1 (es) 2013-06-05
MA34878B1 (fr) 2014-02-01
MY171994A (en) 2019-11-11
CO6781549A2 (es) 2013-10-31
EP2646025B1 (en) 2017-03-15
CN103313709A (zh) 2013-09-18
KR101855358B1 (ko) 2018-05-04
TWI629060B (zh) 2018-07-11
US20130324535A1 (en) 2013-12-05
BR112013013369A8 (pt) 2018-01-09
SG190745A1 (en) 2013-07-31
NZ612119A (en) 2014-06-27
BR112013013369A2 (pt) 2016-09-06
HUE033488T2 (en) 2017-12-28
PL2646025T3 (pl) 2017-09-29
TR201708567T4 (tr) 2019-01-21
UA112638C2 (uk) 2016-10-10
PT2646025T (pt) 2017-06-26
EP2646025A1 (en) 2013-10-09
TW201249805A (en) 2012-12-16
JP6027014B2 (ja) 2016-11-16
CA2819442A1 (en) 2012-06-07
TN2013000227A1 (en) 2014-11-10
DK2646025T3 (en) 2017-06-06
ZA201304966B (en) 2014-09-25
MX2013006140A (es) 2013-07-03
WO2012072782A1 (en) 2012-06-07
CA2819442C (en) 2018-06-12
RU2585095C2 (ru) 2016-05-27
ES2626672T3 (es) 2017-07-25
LT2646025T (lt) 2017-06-12
AU2011334880B2 (en) 2016-09-15
RS56081B1 (sr) 2017-10-31
KR20130135881A (ko) 2013-12-11
ME02852B (me) 2018-04-20
AU2011334880A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CY1118680T1 (el) Φαρμακευτικη συνθεση
CL2012003385A1 (es) Tratamiento para la incontinencia.
EA201171367A1 (ru) Винилиндазолильные соединения
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
CR20150217A (es) Inhibidores de histona demetilasas
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201291194A1 (ru) Индолы
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
UY34582A (es) Anticuerpos anti-cxcr3
TR201909271T4 (tr) Testosteron formülasyonları.
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
CL2010000872A1 (es) Martillo medico para reflejos que incorpora sensores y transmision de datos.
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
CY1117251T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης